Biogen Inc. (0R1B.L)
USD 125.14
(-4.74%)
USD 125.14
(-4.74%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 2.52 Billion USD | 87.99% |
| 2022 | 1.34 Billion USD | -0.53% |
| 2021 | 1.35 Billion USD | 26.47% |
| 2020 | 1.06 Billion USD | 32.88% |
| 2019 | 804.2 Million USD | -13.52% |
| 2018 | 929.9 Million USD | 3.01% |
| 2017 | 902.7 Million USD | -9.87% |
| 2016 | 1 Billion USD | 12.11% |
| 2015 | 893.4 Million USD | 11.12% |
| 2014 | 804.02 Million USD | 22.01% |
| 2013 | 659 Million USD | 47.31% |
| 2012 | 447.37 Million USD | 36.88% |
| 2011 | 326.84 Million USD | 13.07% |
| 2010 | 289.06 Million USD | -1.66% |
| 2009 | 293.95 Million USD | 11.51% |
| 2008 | 263.6 Million USD | 12.66% |
| 2007 | 233.98 Million USD | 38.37% |
| 2006 | 169.1 Million USD | -7.5% |
| 2005 | 182.81 Million USD | -27.17% |
| 2004 | 251.01 Million USD | -49.43% |
| 2003 | 496.34 Million USD | 420.4% |
| 2002 | 95.37 Million USD | 116.24% |
| 2001 | 44.1 Million USD | 10.14% |
| 2000 | 40.04 Million USD | -20.8% |
| 1999 | 50.56 Million USD | 90.21% |
| 1998 | 26.58 Million USD | -28.54% |
| 1997 | 37.2 Million USD | -22.31% |
| 1996 | 47.88 Million USD | 0.0% |
| 1995 | - USD | 0.0% |
| 1994 | - USD | 0.0% |
| 1993 | - USD | 0.0% |
| 1992 | - USD | 0.0% |
| 1991 | - USD | 0.0% |
| 1990 | - USD | 0.0% |
| 1989 | - USD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 2.51 Billion USD | -0.42% |
| 2024 Q2 | 2.5 Billion USD | -0.43% |
| 2024 Q3 | 2.46 Billion USD | -1.47% |
| 2023 Q3 | 2.98 Billion USD | 123.65% |
| 2023 Q2 | 1.33 Billion USD | 4.1% |
| 2023 FY | 2.52 Billion USD | 87.99% |
| 2023 Q1 | 1.28 Billion USD | -4.72% |
| 2023 Q4 | 2.52 Billion USD | -15.26% |
| 2022 Q1 | 1.21 Billion USD | -10.07% |
| 2022 FY | 1.34 Billion USD | -0.53% |
| 2022 Q4 | 1.34 Billion USD | -2.23% |
| 2022 Q3 | 1.37 Billion USD | 6.24% |
| 2022 Q2 | 1.29 Billion USD | 6.48% |
| 2021 FY | 1.35 Billion USD | 26.47% |
| 2021 Q1 | 1.17 Billion USD | 9.66% |
| 2021 Q4 | 1.35 Billion USD | 0.27% |
| 2021 Q3 | 1.34 Billion USD | 7.42% |
| 2021 Q2 | 1.25 Billion USD | 7.08% |
| 2020 Q2 | 952.7 Million USD | 10.93% |
| 2020 Q4 | 1.06 Billion USD | 3.98% |
| 2020 Q3 | 1.02 Billion USD | 7.87% |
| 2020 FY | 1.06 Billion USD | 32.88% |
| 2020 Q1 | 858.8 Million USD | 6.79% |
| 2019 Q4 | 804.2 Million USD | 6.97% |
| 2019 Q3 | 751.8 Million USD | -3.21% |
| 2019 Q1 | 770.2 Million USD | -17.17% |
| 2019 Q2 | 776.7 Million USD | 0.84% |
| 2019 FY | 804.2 Million USD | -13.52% |
| 2018 FY | 929.9 Million USD | 3.01% |
| 2018 Q2 | 931.7 Million USD | 4.59% |
| 2018 Q3 | 916.6 Million USD | -1.62% |
| 2018 Q4 | 929.9 Million USD | 1.45% |
| 2018 Q1 | 890.8 Million USD | -1.32% |
| 2017 Q4 | 902.7 Million USD | -10.38% |
| 2017 Q2 | 936.5 Million USD | 1.62% |
| 2017 Q1 | 921.6 Million USD | -7.99% |
| 2017 FY | 902.7 Million USD | -9.87% |
| 2017 Q3 | 1 Billion USD | 7.55% |
| 2016 Q1 | 964.6 Million USD | 7.97% |
| 2016 Q2 | 996.4 Million USD | 3.3% |
| 2016 Q3 | 1 Billion USD | 1.33% |
| 2016 FY | 1 Billion USD | 12.11% |
| 2016 Q4 | 1 Billion USD | -0.8% |
| 2015 Q2 | 865.73 Million USD | 4.89% |
| 2015 Q3 | 918.92 Million USD | 6.14% |
| 2015 Q1 | 825.34 Million USD | 2.65% |
| 2015 Q4 | 893.4 Million USD | -2.78% |
| 2015 FY | 893.4 Million USD | 11.12% |
| 2014 Q2 | 715.93 Million USD | 6.42% |
| 2014 Q3 | 753.06 Million USD | 5.19% |
| 2014 Q1 | 672.75 Million USD | 2.09% |
| 2014 FY | 804.02 Million USD | 22.01% |
| 2014 Q4 | 804.02 Million USD | 6.77% |
| 2013 Q3 | 614.48 Million USD | 7.73% |
| 2013 FY | 659 Million USD | 47.31% |
| 2013 Q4 | 659 Million USD | 7.25% |
| 2013 Q2 | 570.39 Million USD | 12.6% |
| 2013 Q1 | 506.55 Million USD | 13.23% |
| 2012 Q4 | 447.37 Million USD | 13.86% |
| 2012 FY | 447.37 Million USD | 36.88% |
| 2012 Q1 | 337.61 Million USD | 3.3% |
| 2012 Q2 | 362.94 Million USD | 7.5% |
| 2012 Q3 | 392.9 Million USD | 8.25% |
| 2011 Q1 | 295.26 Million USD | 2.14% |
| 2011 Q3 | 310.93 Million USD | 0.87% |
| 2011 FY | 326.84 Million USD | 13.07% |
| 2011 Q4 | 326.84 Million USD | 5.12% |
| 2011 Q2 | 308.25 Million USD | 4.4% |
| 2010 Q1 | 280.03 Million USD | -4.73% |
| 2010 FY | 289.06 Million USD | -1.66% |
| 2010 Q4 | 289.06 Million USD | 7.33% |
| 2010 Q3 | 269.31 Million USD | 0.54% |
| 2010 Q2 | 267.87 Million USD | -4.34% |
| 2009 Q3 | 278.68 Million USD | 3.78% |
| 2009 Q4 | 293.95 Million USD | 5.48% |
| 2009 FY | 293.95 Million USD | 11.51% |
| 2009 Q1 | 268.07 Million USD | 1.7% |
| 2009 Q2 | 268.52 Million USD | 0.17% |
| 2008 Q1 | 237.17 Million USD | 1.36% |
| 2008 Q4 | 263.6 Million USD | 5.5% |
| 2008 Q3 | 249.85 Million USD | -2.03% |
| 2008 FY | 263.6 Million USD | 12.66% |
| 2008 Q2 | 255.02 Million USD | 7.53% |
| 2007 FY | 233.98 Million USD | 38.37% |
| 2007 Q1 | 186.22 Million USD | 10.12% |
| 2007 Q2 | 207.89 Million USD | 11.64% |
| 2007 Q3 | 222.85 Million USD | 7.2% |
| 2007 Q4 | 233.98 Million USD | 4.99% |
| 2006 Q1 | 191.02 Million USD | 4.49% |
| 2006 Q2 | 147.02 Million USD | -23.03% |
| 2006 Q3 | 155.11 Million USD | 5.51% |
| 2006 FY | 169.1 Million USD | -7.5% |
| 2006 Q4 | 169.1 Million USD | 9.01% |
| 2005 Q4 | 182.81 Million USD | -19.63% |
| 2005 Q1 | 236.62 Million USD | -5.73% |
| 2005 Q2 | 243.53 Million USD | 2.92% |
| 2005 Q3 | 227.46 Million USD | -6.6% |
| 2005 FY | 182.81 Million USD | -27.17% |
| 2004 FY | 251.01 Million USD | -49.43% |
| 2004 Q3 | 246.36 Million USD | 5.84% |
| 2004 Q1 | 311.39 Million USD | -37.26% |
| 2004 Q2 | 232.76 Million USD | -25.25% |
| 2004 Q4 | 251.01 Million USD | 1.89% |
| 2003 Q3 | 93.98 Million USD | 12.55% |
| 2003 Q2 | 83.5 Million USD | -10.89% |
| 2003 FY | 496.34 Million USD | 420.4% |
| 2003 Q4 | 496.34 Million USD | 428.13% |
| 2003 Q1 | 93.7 Million USD | -1.75% |
| 2002 FY | 95.37 Million USD | 116.24% |
| 2002 Q3 | 23.7 Million USD | 71.7% |
| 2002 Q2 | 13.8 Million USD | 88.15% |
| 2002 Q1 | 7.33 Million USD | -83.36% |
| 2002 Q4 | 95.37 Million USD | 302.3% |
| 2001 Q3 | 230 Thousand USD | -99.48% |
| 2001 Q2 | 43.99 Million USD | -9.24% |
| 2001 Q1 | 48.47 Million USD | 21.05% |
| 2001 FY | 44.1 Million USD | 10.14% |
| 2001 Q4 | 44.1 Million USD | 19077.39% |
| 2000 Q4 | 40.04 Million USD | -28.84% |
| 2000 FY | 40.04 Million USD | -20.8% |
| 2000 Q1 | 58.07 Million USD | 14.85% |
| 2000 Q3 | 56.27 Million USD | -5.78% |
| 2000 Q2 | 59.73 Million USD | 2.85% |
| 1999 FY | 50.56 Million USD | 90.21% |
| 1999 Q3 | - USD | 0.0% |
| 1999 Q4 | 50.56 Million USD | 0.0% |
| 1999 Q2 | - USD | 0.0% |
| 1999 Q1 | - USD | -100.0% |
| 1998 Q1 | - USD | -100.0% |
| 1998 Q4 | 26.58 Million USD | 0.0% |
| 1998 Q3 | - USD | 0.0% |
| 1998 Q2 | - USD | 0.0% |
| 1998 FY | 26.58 Million USD | -28.54% |
| 1997 Q3 | - USD | 0.0% |
| 1997 Q1 | - USD | -100.0% |
| 1997 Q2 | - USD | 0.0% |
| 1997 Q4 | 37.2 Million USD | 0.0% |
| 1997 FY | 37.2 Million USD | -22.31% |
| 1996 Q4 | 47.88 Million USD | 185.05% |
| 1996 Q1 | 11.9 Million USD | 0.0% |
| 1996 Q2 | 16.6 Million USD | 39.5% |
| 1996 Q3 | 16.8 Million USD | 1.2% |
| 1996 FY | 47.88 Million USD | 0.0% |
| 1995 Q4 | - USD | 0.0% |
| 1995 Q3 | - USD | 0.0% |
| 1995 Q2 | - USD | 0.0% |
| 1995 FY | - USD | 0.0% |
| 1995 Q1 | - USD | 0.0% |
| 1994 Q4 | - USD | 0.0% |
| 1994 Q1 | - USD | 0.0% |
| 1994 Q2 | - USD | 0.0% |
| 1994 Q3 | - USD | 0.0% |
| 1994 FY | - USD | 0.0% |
| 1993 Q1 | - USD | 0.0% |
| 1993 Q2 | - USD | 0.0% |
| 1993 Q4 | - USD | 0.0% |
| 1993 Q3 | - USD | 0.0% |
| 1993 FY | - USD | 0.0% |
| 1992 Q4 | - USD | 0.0% |
| 1992 FY | - USD | 0.0% |
| 1992 Q2 | - USD | 0.0% |
| 1992 Q3 | - USD | 0.0% |
| 1992 Q1 | - USD | 0.0% |
| 1991 Q3 | - USD | 0.0% |
| 1991 FY | - USD | 0.0% |
| 1991 Q2 | - USD | 0.0% |
| 1991 Q4 | - USD | 0.0% |
| 1991 Q1 | - USD | 0.0% |
| 1990 Q4 | - USD | 0.0% |
| 1990 FY | - USD | 0.0% |
| 1990 Q2 | - USD | 0.0% |
| 1990 Q1 | - USD | 0.0% |
| 1990 Q3 | - USD | 0.0% |
| 1989 Q4 | - USD | 0.0% |
| 1989 Q3 | - USD | 0.0% |
| 1989 FY | - USD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| uniQure N.V. | 12.02 Million USD | -20919.627% |
| Agios Pharmaceuticals, Inc. | 19.07 Million USD | -13149.109% |
| Amicus Therapeutics, Inc. | 59.69 Million USD | -4133.785% |
| Atara Biotherapeutics, Inc. | 9.7 Million USD | -25939.563% |
| bluebird bio, Inc. | 22.91 Million USD | -10927.532% |
| Cara Therapeutics, Inc. | 2.82 Million USD | -89492.343% |
| Imunon, Inc. | - USD | -Infinity% |
| Editas Medicine, Inc. | - USD | -Infinity% |
| IQVIA Holdings Inc. | - USD | -Infinity% |
| Mettler-Toledo International Inc. | 385.86 Million USD | -554.996% |
| Myriad Genetics, Inc. | 20.1 Million USD | -12474.129% |
| Neurocrine Biosciences, Inc. | 38.3 Million USD | -6498.956% |
| Supernus Pharmaceuticals, Inc. | 77.4 Million USD | -3165.037% |
| Verastem, Inc. | - USD | -Infinity% |
| Walgreens Boots Alliance, Inc. | 8.32 Billion USD | 69.623% |
| Waters Corporation | 516.23 Million USD | -389.582% |
| Thermo Fisher Scientific Inc. | 5.08 Billion USD | 50.326% |
| Nektar Therapeutics | 16.1 Million USD | -15597.162% |
| Perrigo Company plc | 1.14 Billion USD | -121.527% |
| Dynavax Technologies Corporation | 53.29 Million USD | -4642.728% |
| Illumina, Inc. | 587 Million USD | -330.562% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Iovance Biotherapeutics, Inc. | 10.37 Million USD | -24267.528% |
| Heron Therapeutics, Inc. | 42.11 Million USD | -5901.9% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |
| BioMarin Pharmaceutical Inc. | 1.1 Billion USD | -128.273% |
| Sangamo Therapeutics, Inc. | - USD | -Infinity% |
| Evolus, Inc. | 10.99 Million USD | -22880.542% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| Aclaris Therapeutics, Inc. | - USD | -Infinity% |
| Regeneron Pharmaceuticals, Inc. | 2.58 Billion USD | 2.058% |
| Esperion Therapeutics, Inc. | 65.62 Million USD | -3751.394% |
| FibroGen, Inc. | 41.56 Million USD | -5980.597% |
| Agilent Technologies, Inc. | 1.03 Billion USD | -145.141% |
| OPKO Health, Inc. | 65.69 Million USD | -3747.055% |
| Homology Medicines, Inc. | - USD | -Infinity% |
| Geron Corporation | - USD | -Infinity% |
| Alnylam Pharmaceuticals, Inc. | 89.14 Million USD | -2735.124% |
| Exelixis, Inc. | 17.32 Million USD | -14489.852% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | - USD | -Infinity% |
| Zoetis Inc. | 2.56 Billion USD | 1.427% |
| Axsome Therapeutics, Inc. | 15.13 Million USD | -16599.042% |
| Abeona Therapeutics Inc. | -2.44 Million USD | 103512.439% |
| Vertex Pharmaceuticals Incorporated | 738.8 Million USD | -242.095% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Ionis Pharmaceuticals, Inc. | 28.42 Million USD | -8791.469% |
| Sarepta Therapeutics, Inc. | 322.85 Million USD | -682.819% |
| Corcept Therapeutics Incorporated | 7.73 Million USD | -32595.99% |
| Halozyme Therapeutics, Inc. | 127.6 Million USD | -1880.705% |
| Blueprint Medicines Corporation | 21.22 Million USD | -11808.778% |
| Insmed Incorporated | 83.24 Million USD | -2935.989% |
| TG Therapeutics, Inc. | 39.82 Million USD | -6246.584% |
| Incyte Corporation | 62.97 Million USD | -3913.53% |
| Emergent BioSolutions Inc. | 328.9 Million USD | -668.44% |